research The Role of Oral Contraceptives in the Treatment of Hyperandrogenic Disorders
Oral contraceptives help treat hyperandrogenic disorders, improving symptoms like excessive hair and acne.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Clinical management of patients withASXL1mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance
Patients with Bohring-Opitz syndrome and ASXL1 mutations need regular kidney ultrasounds to check for tumors.
research Cutaneous Reactions to Chemotherapeutic Agents
Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.
research Acorus calamus: a bio-reserve of medicinal values
*Acorus calamus* has many medicinal benefits but needs more safety research.
research Androgenetic alopecia in males: a histopathological and ultrastructural study
Hair loss in males involves inflammation, collagen buildup, and follicle damage, with severity increasing with age and baldness duration.
research Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation
Dutasteride-containing mesotherapy effectively treats female hair loss, improving density and thickness with minimal side effects.
research Cutaneous Side Effects of Oral Contraceptives
Oral contraceptives can cause skin issues like dark patches, acne, yeast infections, sensitivity to light, spider veins, skin rashes, and hair loss.
research Six-year Retrospective Review of Drug Reaction with Eosinophilia and Systemic Symptoms
Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.
research Objective outcome measures: Collecting meaningful data on alopecia areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research Preparation of novel polymeric microspheres for controlled release of finasteride
PPCM microspheres allow controlled finasteride release over 24 hours.